Glycosmedia

Diabetes News Service

Privacy & Cookies: This site uses cookies. By continuing to use this website, you agree to their use.
To find out more, including how to control cookies, see here: Cookies Policy
  • News
  • Archive
  • Categories & Tags
  • Journal Watch
  • Updates
  • Education
  • Reviews
  • About us ▼
    • About Glycosmedia
    • Editorial Team
    • Frequently asked questions
    • Comments
    • Press Releases
    • Disclaimer
  • Subscribe
  • Contact

Editorial opinion

June 23rd 2016

Given the epidemiology of diabetes, it is understandable that there is a shift in routine management from secondary to primary care. Whether there is enough support for primary care is debatable but usually there is enough guidance to manage non insulin treated patients – and even those on non complex insulin regimes. So far so good! However, there is a risk that patients with T1DM may get caught up in the rush to transfer care out of hospital. In fact, this week’s episode of Pulse describes a commissioning intention of a CCG to actively promote it.

However, it is often not understood that T1 and T2 diabetes behave like two separate conditions when it comes to glucose lowering. Furthermore, there is a major difference in the education that these patients require, specifically the intricacies of carbohydrate counting, correction doses and the detailed awareness of the profiles of a variety of rapid and longer acting insulin, not to mention pump therapy.  Type 1 patients often possess. There is also the higher risk of hypoglycaemia including unawareness with all the associated issues including the impact on driving.

Whilst it is possible that practices have the skills to manage T1 patients, it is unlikely that this can be done without significant support from specialist care. This can come in a variety of ways including education sessions, virtual or e-consultation to name a couple. It is unclear from the proposals as to how this will be done. Furthermore, there is no acknowledgement that T1 patients are often highly motivated and educated about their condition, commonly having more knowledge about ‘their’ diabetes than the health care professional treating them. Significant input would be necessary to convince these patients that the transfer of care does not come at the expense of clinical care.

Overall, the location of care is not important, ensuring that the right patient is seen by the right clinician is vital to ensure that this group of patients are not disadvantaged.

Dr. Mark Freeman

Categories: News

Categories:

Subscribe

subscribe-iconFREE weekly updates by email Please CLICK HERE

Gold Sponsors

AstraZenecaNovo NordiskNapp DiabetesBoehringer Ingelheim

Silver Sponsors

Welsh Endocrinology and Diabetes Society (WEDS)Abbott Diabetes CareAbout Ascensia Diabetes Care

FUNDING NOTICE

The Glycosmedia website and newsletter has been made possible with funding support from our sponsors. None of our sponsors have control over the content of the website, newsletter, apps, Twitter feed or RSS newsfeed.

For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com

Advertisers

CRC Press

The organisations advertising in this section do not have any input into, or editorial control over the content of this website.

News Archive

calendar-iconNews Archive ››

Categories

  • Audits
  • Bariatric
  • Biochemistry
  • Cardiovascular
  • Devices
  • Diagnosis
  • Diet
  • Education
  • Epidemiology
  • Genetics
  • Gestational
  • Guidance
  • Guidelines
  • Hepatology
  • Hypertension
  • Immunology
  • Management
  • Media
  • Medication
  • Meetings
  • Monitoring
  • Nephrology
  • Neuropathy
  • Nephropathy
  • Obesity
  • Ophthalmology
  • Paediatrics
  • Pathology
  • Pharma
  • Pharmacology
  • Physiology
  • Podiatry
  • Prediabetes
  • Prevalence
  • Prevention
  • Psychological
  • Reports
  • Research
  • Screening
  • Sponsorship
  • Technology
  • Testing
  • Transplantation
  • Treatment
  • Wound Care

To see all articles associated with a category just click on the category name.

Popular Tags

ADA BMI canagliflozin CGM CKD closed-loop COVID-19 dapagliflozin DPP4 DPP4 inhibitors Empagliflozin exenatide GLP-1 RA GLP-1RA GLP1 glycaemic control HbA1c heart failure hyperglycemia hypoglycemia incretin insulin insulin pump Insulin resistance Ketoacidosis liraglutide metformin microvascular mortality NICE pioglitazone retinopathy semaglutide SGLT2 inhibitors sitagliptin statin sulfonylureas Type 1 Diabetes Type 2 Diabetes Vitamin D

To see all articles associated with a tag just click on the tag name.

Complete list of Tags ››

Recent Book and Product Reviews

  • Oxford Handbook of Medical Ethics and Law
  • Textbook of Emergency Cardiology
  • Braunwald’s Heart Disease
  • Conn’s Current Therapy 2022

Recent Diabetes Updates

  • National Diabetes Audit.
  • Funding bids
  • Publication of Studies During 2016 – Type 2 Diabetes
  • “Attitudes to obesity” findings from the 2015 survey

Join us on Facebook

Join us on Facebook

Please share Glycosmedia:

Follow us on Twitter

My Tweets

mobileGlycosmedia is also available as an App:

For iPhone and iPad | For Android devices


Sponsorship and Advertising

For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com


Website by Wired up Wales

Copyright © 2022 Glycosmedia Partnership